It is necessary to provide Kymriah treatment accessibility

By | translator Choi HeeYoung

21.08.30 13:46:00

가나다라 0

Utilize RWE data from The HIRA to analyze the survival period of DLBCL patients who failed secondary treatment

MOS 4.73 months, 70% after failure of secondary treatment remains salvage chemotherapy

It is necessary to provide Kymriah treatment accessibility with high response rates

Novartis Korea (CEO Kim Skafte Mortensen) announced on the 30th that the ICBMT released the results of a study that analyzed the treatment of DLBCL patients in Korea from August 26 at ICBMT.

DLBCL is an aggressive lymphoma that accounts for about 40% of non-Hodgkin lymphoma. Although most standard treatments show abnormalities in part, it is known that 10 to 15% of patients do not respond to primary treatments and 20 to 35% experience recurrence.

The study was conducted to identify the demographic characteristics and treatment patterns and prognosis of DLBCL patients in Korea. Led by Professor Park Mi-hye, College of Pharmacy, Sungkyunkwan University, a total of 4931 claims of the HIRA we

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)